These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1423 related articles for article (PubMed ID: 17697906)

  • 1. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
    Hale M; Tudor IC; Khanna S; Thipphawong J
    Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone.
    Ward A; Bozkaya D; Fleischmann J; Dubois D; Sabatowski R; Caro JJ
    Curr Med Res Opin; 2007 Oct; 23(10):2333-45. PubMed ID: 17697453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized study to demonstrate noninferiority of once-daily OROS(®) hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain.
    Binsfeld H; Szczepanski L; Waechter S; Richarz U; Sabatowski R
    Pain Pract; 2010; 10(5):404-15. PubMed ID: 20384968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained safety and efficacy of once-daily hydromorphone extended-release (OROS® hydromorphone ER) compared with twice-daily oxycodone controlled-release over 52 weeks in patients with moderate to severe chronic noncancer pain.
    Richarz U; Waechter S; Sabatowski R; Szczepanski L; Binsfeld H
    Pain Pract; 2013 Jan; 13(1):30-40. PubMed ID: 22510252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
    Kivitz A; Ma C; Ahdieh H; Galer BS
    Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of a double-blind, placebo-controlled, fixed-dose assessment of once-daily OROS® hydromorphone ER in patients with moderate to severe pain associated with chronic osteoarthritis.
    Rauck R; Rapoport R; Thipphawong J
    Pain Pract; 2013 Jan; 13(1):18-29. PubMed ID: 22537100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 microg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, parallel-group noninferiority study.
    Karlsson M; Berggren AC
    Clin Ther; 2009 Mar; 31(3):503-13. PubMed ID: 19393841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety evaluation of once-daily OROS hydromorphone in patients with chronic low back pain: a pilot open-label study (DO-127).
    Wallace M; Skowronski R; Khanna S; Tudor IC; Thipphawong J
    Curr Med Res Opin; 2007 May; 23(5):981-9. PubMed ID: 17519065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study.
    Hartrick C; Van Hove I; Stegmann JU; Oh C; Upmalis D
    Clin Ther; 2009 Feb; 31(2):260-71. PubMed ID: 19302899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study.
    Yu S; Shen W; Yu L; Hou Y; Han J; Richards HM
    J Pain; 2014 Aug; 15(8):835-44. PubMed ID: 24846822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee.
    Babul N; Noveck R; Chipman H; Roth SH; Gana T; Albert K
    J Pain Symptom Manage; 2004 Jul; 28(1):59-71. PubMed ID: 15223085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-Related Quality-of-Life Outcomes in Patients Treated with Push-Pull OROS Hydromorphone versus Extended-Release Oxycodone for Chronic Hip or Knee Osteoarthritis Pain: A Randomized, Open-Label, Parallel-Group, Multicenter Study.
    Gajria K; Kosinski M; Schein J; Kavanagh S; Dubois D
    Patient; 2008 Jul; 1(3):223-38. PubMed ID: 22272928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
    Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
    Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-daily OROS hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study.
    Wallace M; Rauck RL; Moulin D; Thipphawong J; Khanna S; Tudor IC
    Int J Clin Pract; 2007 Oct; 61(10):1671-6. PubMed ID: 17877652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post hoc analysis of a randomized, double-blind, placebo-controlled efficacy and tolerability study of tramadol extended release for the treatment of osteoarthritis pain in geriatric patients.
    Vorsanger G; Xiang J; Jordan D; Farrell J
    Clin Ther; 2007; 29 Suppl():2520-35. PubMed ID: 18164919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety, tolerability, and efficacy of OROS hydromorphone in patients with chronic pain.
    Wallace M; Moulin DE; Rauck RL; Khanna S; Tudor IC; Skowronski R; Thipphawong J
    J Opioid Manag; 2009; 5(2):97-105. PubMed ID: 19507806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain.
    Palangio M; Northfelt DW; Portenoy RK; Brookoff D; Doyle RT; Dornseif BE; Damask MC
    J Pain Symptom Manage; 2002 May; 23(5):355-68. PubMed ID: 12007754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Tolerability of Once-Daily OROS(®) hydromorphone extended-release in opioid-tolerant adults with moderate-to-severe chronic cancer and noncancer pain: pooled analysis of 11 clinical studies.
    Nalamachu SR; Kutch M; Hale ME
    J Pain Symptom Manage; 2012 Dec; 44(6):852-65. PubMed ID: 22795050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion from standard opioid therapy to once-daily oral extended-release hydromorphone in patients with chronic cancer pain.
    Wallace M; Rauck RL; Moulin D; Thipphawong J; Khanna S; Tudor IC
    J Int Med Res; 2008; 36(2):343-52. PubMed ID: 18380946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability, Safety, and Effectiveness of Oxycodone DETERx in Elderly Patients ≥65 Years of Age with Chronic Low Back Pain: A Randomized Controlled Trial.
    Kopecky EA; Vaughn B; Lagasse S; O'Connor M
    Drugs Aging; 2017 Aug; 34(8):603-613. PubMed ID: 28600725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 72.